Country
United States
Merck & Co Inc has voluntarily withdrawn the metastatic small cell lung cancer indication for Keytruda (pembrolizumab) following the results of a Phase 3 study which didn’t support the terms of its earlier accelerated approval f
Full text available to subscribers only. Click here for information on subscribing to MedNous.